months; 165 patients (37.7%) had no cirrhosis and 256 patients (58.4%) had no hepatitis. Overall, all staging systems were significantly less predictive of OS in patients who did not have cirrhosis or hepatitis. Conclusion: Our results advocate the need to further stratify HCC based on cirrhosis and hepatitis status, which may change patient risk-stratification and, ultimately, treatment decisions.
Introduction
In the USA, the incidence of hepatocellular carcinoma (HCC) has risen steadily over the past 2 decades, and is now the fastest growing cause of cancer-related deaths in American men [1] . HCC develops as a consequence of underlying chronic liver disease (CLD); therefore, this syndrome of the two-disease state directly affects survival, which in turn affects patients' prognostic staging and treatment allocation.
Nearly 80% of HCC patients have nonsurgical HCC; thus, this group of HCC patients has emerged as the standard patient population for local and systemic therapies in routine practice and is the main focus of HCC clinical trials. However, HCC prognostication and treatment allocation of this patient population is very challenging, mainly due to the lack of a universal HCC prognostic staging system. Notably, the key roles of prognostic HCC staging are: (1) to accurately predict patient survival, (2) to guide therapy decisions and (3) to stratify patients in clinical trials, which is crucial to interpreting and comparing the results of clinical trials. Therefore, HCC staging plays a pivotal role in managing nonsurgical HCC.
Several HCC staging systems based on multiple prognostic factors including CLD status and tumor parameters were developed in the 1980s and 1990s by different centers in Europe and Asia, with different demographics and risk factors [2] [3] [4] [5] [6] . However, none were developed from a US patient population, and none of them embrace all the needs of management of this heterogeneous patient population [6] . Notably, commonly used HCC staging systems are based primarily on data from patients with viral hepatitis-and/or cirrhosis-related HCC [2] [3] [4] [5] [6] ( table 1 ) . Viral hepatitis incidence, mainly C in Europe and B in Asia, ranged between 82.3 and 100%, and cirrhosis incidence ranged between 77 and 100% in patients whose data were used to establish these staging systems. However, newly identified HCC risk factors in the USA, including those unrelated to hepatitis or advanced cirrhosis, such as the metabolic syndrome and nonalcoholic steatohepatitis, NASH, which can lead to HCC without apparent cirrhosis [7] , in addition to recent advances and increased use of HCC local and systemic therapies, have markedly influenced the natural history of HCC and presumably the ability of current HCC staging systems to predict the prognosis and overall survival (OS) of patients. In fact, the cause-specific OS rates for HCC in the USA nearly doubled between 1992 and 1993, and between 2003 and 2004 [8] .
Furthermore, based on two recent studies from major US medical oncology centers, patients were found to have a higher incidence of advanced-stage HCC, defined as Barcelona Clinic Liver Cancer (BCLC) stage C (65.6-85%) [9, 10] and lower incidence of cirrhosis (55-60.1%) [9, 10] , which represented direct referrals from primary care physicians without a significant history of CLDs. Meanwhile major transplant centers were more likely to have HCC patients with cirrhosis (88-98%) [11, 12] and a lower percentage of BCLC advanced stage C (10-31%) [11, 12] because of adopting regular HCC surveillance strategies for their large established population of CLD.
Therefore, we hypothesized that currently available HCC staging systems are less predictive of OS duration in the changing US patient population at oncology centers presenting with lower prevalence of viral hepatitis and cirrhosis. Our study goal was to compare the accuracy of OS prediction of commonly used HCC staging systems in the recent HCC patient population with and without cirrhosis or viral hepatitis at our oncology center, since viral hepatitis and cirrhosis have independent effects on HCC natural history and HCC patient survival.
Patients and Methods

Patient Population
The University of Texas MD Anderson Cancer Center's Institutional Review Board approved the protocol for the present study as part of the currently ongoing HCC case control study, and patients provided written informed consent before participating in the study. In the present study, we prospectively enrolled and collected data from HCC patients who were evaluated and treated recently at our institution. The study inclusion criterion was US residency with histologically confirmed HCC or HCC tumors that met the imaging criteria set forth by the American Association for the Study of the Liver (AASLD) after 2005. Patients were excluded if they had a nonliver cancer concurrently or within the preceding 5 years.
Definition of Cirrhosis
The diagnosis of cirrhosis was based on the presence of pathologic and/or radiologic evidence.
Data Collection
For each patient, we obtained the following baseline demographic data: clinical parameters, including Eastern Cooperative Oncology Group (ECOG) performance status score, cirrhosis status based on histologic, imaging or biochemical evidence, alcohol consumption and Child-Pugh score; laboratory parameters, including hepatitis serology and those needed to ascertain disease stage using the 5 systems we evaluated, and radiologic parameters of tumor morphology. We used the collected data to stage patients according to the BCLC stage, Cancer of the Liver Italian Program (CLIP) score, TNM (tumor, nodes, metastasis; 6th edition) stage, Okuda stage, and Chinese University Prognostic Index (CUPI) score, which were obtained for all patients. For the CUPI staging system, the TNM stage based on the 5th edition of the American Joint Committee on Cancer (AJCC) system was calculated, and bilirubin values were converted from milligrams per deciliter to micromoles per liter. OS duration was calculated from the time of baseline staging calculation to the last follow-up or death.
Statistical Analysis
All statistical analyses were performed using the STATA software program (version 11.0; StataCorp, College Station, Tex., USA). Kaplan-Meier survival analyses were performed to generate OS curves. Log-rank tests were used to analyze the differences in OS between prognostic strata of individual staging systems. Univariate and multivariate analyses were performed to identify independent prognostic factors for OS. The power of individual staging systems to predict OS duration was assessed using Harrell's Correspondence (C)-index, and U-statistics compared Harrell's C-indices of different staging systems. The Somers' D package in STATA was used to generate 95% confidence intervals (CIs) and p values for the C-indices, which were validated using bootstrap analysis.
To determine whether patients' hepatitis or cirrhosis status affected the power of individual staging systems to predict OS duration, we divided patients into different groups based on their hepatitis and cirrhosis status. For each subgroup, we compared the Harrell's C-indices of the 5 staging systems and computed p values to determine which staging system best predicted OS duration.
Results
Patient Characteristics
Between January 2001 and February 2011, 438 consecutive HCC patients were enrolled. Patient baseline characteristics and staging are summarized in table 2 ; 165 patients (37.7%) had no cirrhosis and 256 patients (58.4%) had no hepatitis, and 140 patients had hepatitis C (32%), 36 patients had hepatitis B (8.2%) and 6 patients had both hepatitis C and B (1.4%). Most patients had advanced HCC tumors based on the AJCC TNM staging criteria (6th edition); 268 patients (61.2%) had stage III-IV tumors at presentation. Based on BCLC staging, 351 (86.5%) had nonsurgical stages B-C-D, while 276 patients (63%) were asymptomatic at presentation, and 323 patients (73.7%) had class A Child-Pugh scores, indicating preserved liver function. Systemic therapies were received by 184 patients (42%), which were mainly targeted therapies: erlotinib (40 patients), erlotinib plus bevacizumab (59 patients), thalidomide (37 patients), interferon plus 5-fluorouracil (34 patients), TAC-101, an oral synthetic retinoid (33 patients), and sorafenib (138 patients).
OS Estimates
The median OS duration was 13.9 months (95% CI 11.01-15.85) for the entire group, 12.6 months (95% CI 9.4-15.4) for patients with cirrhosis and 14.9 months (95% CI 11.4-23.2) for patients without cirrhosis (p = 0.003), while OS for hepatitis C patients was 10.6 months (95% CI 7.1-14.2), OS for patients with hepatitis B was 6.9 months (95% CI 3.5-30.8) and OS for patients with no hepatitis was 15.6 months (95% CI 12.6-21.8; p = 0.002; see Kaplan-Meier curves in fig. 1 Values in parentheses are either percentages or 95% CI. HCV = Hepatitis C virus; HBV = hepatitis B virus; AFP = α-fetoprotein. Table 3 shows the OS of all patients by all 5 staging systems, and table 4 shows the Harrell's C-indices and 95% CIs for all staging systems of the entire cohort and per subgroup based on the cirrhosis and hepatitis status. For the entire cohort of 438 patients, CLIP (C-index 0.71, 95% CI 0.68-0.74) followed by CUPI (C-index 0.66, 95% CI 0.63-0.69) and then BCLC (C-index 0.64, 95% CI 0.62-0.67) were the most accurate at predicting OS durations ( table 4 ) . Comparisons of the different staging systems based on hepatitis and cirrhosis status comparing Harrell's C-indices of different staging systems revealed that, overall, the ability of the staging systems to predict OS duration was significantly stronger in patients who had cirrhosis and patients who had hepatitis than in patients who did not have cirrhosis or hepatitis.
Comparison of Staging Systems
Discussion
In our study, which represents the largest study of HCC staging from a US oncology center, as we expected, based on the recently changing trends in viral hepatitis and cirrhosis incidence in HCC patients at oncology centers, the overall ability of the HCC staging systems to predict OS duration was significantly poorer in patients who had no cirrhosis (37.7%) or viral hepatitis (58.4%). Our study represents the first detailed analysis of the independent effect of cirrhosis and viral hepatitis status on the prognostic accuracy of HCC staging systems. Furthermore, we observed a notable lower prevalence of viral hepatitis and cirrhosis in our patient population than those of the patient populations used to establish the ; table 1 ). This is consistent with and complementary to multiple recent reports indicating the rising incidence of HCC cases that are not associated with viral hepatitis or cirrhosis, specifically among NASH and metabolic syndrome CLDs which can lead to HCC without apparent cirrhosis [7] . Since the presence of cirrhosis and/or viral hepatitis has significant independent prognostic and clinical implications in HCC patients, our results advocate the need to use cirrhosis and hepatitis status as independent stratification criteria for HCC prognostication before clinical trial entry and in clinical practice for the purpose of survival prediction, treatment allocation and comparing results from independent trials.
To compare the prognostic accuracy of different staging systems, we used the C-index which yields values ranging from 0 (no discrimination) to 1 (perfect separation). It has been used to compare the prognostic accuracy of liver scores in several studies, including the landmark prospective study of 3,437 adult liver transplant candidates with CLD to estimate 3-month mortality that established the universal use of the Model for End-Stage Liver Disease (MELD) score to determine organ allocation priorities [13] . The study reported a C-index of 0.83 for the MELD score as compared to 0.76 for the CTP score. While the difference between C-indices was not large (0.07), it was statistically significant.
Interestingly, CLIP had significantly stronger prognostic ability in our patients with hepatitis C (C-index 0.75) than in patients without hepatitis (C-index 0.68), while CUPI had significantly stronger prognostic ability in patients with hepatitis B (C-index 0.71) than in patients without hepatitis (C-index 0.64). This differential performance accuracy of CLIP and CUPI systems in HCC patients based on their hepatitis status may be reflective of patient population similarities to those of the original patient populations used to create the CLIP and CUPI systems ( table 1 ). The CLIP score [2] and BCLC staging [3] were both derived using data primarily from European patients with hepatitis C-related HCC, whereas the Okuda [4] and CUPI [5] systems were derived using data primarily from Asian patients with hepatitis Brelated HCC. However, BCLC performance was not as high as CLIP in our study. This is likely due to the fact that these two systems are conceptually different and cannot be compared directly, because the CLIP score was designed as a prognostic system to stratify HCC patients according to their expected survival into 6 groups regardless of what treatment was received, whereas the BCLC staging was originally designed as a treatment allocation system that links patient survival not only to tumor and liver function status, but also to the treatment received (online suppl. fig. 1 ). Therefore, BCLC evolved as one of the standard systems to allocate therapeutic options and to stratify patients in routine practice and in clinical trials. However, our recent studies and those of others indicated that CLIP is more accurate in predicting survival of advanced nonsurgical HCC patients, most likely because it provides more strata for those patients than BCLC does [9, 10, [14] [15] [16] . Under BCLC, patients with early stages (0 or A) have very detailed tumor parameters and strata, while those with advanced nonsurgical HCC are classified under 2 main broad categories: one stage for local therapies (stage B) and one stage for systemic therapies (stage C). In the current study, 80.1% of patients were categorized under BCLC stages B and C. Furthermore, our study showed a remarkable consistency of the discriminative ability of CLIP score in predicting patient OS. This was defined by a C-index of 0.71 ( table 4 ) with other recent studies from the USA and Europe reporting patients from oncology centers with almost identical C-index scores of 0.71 [17] and 0.69 [10] . However, several studies indicated that about 70-80% of HCC patients are classified under CLIP scores of 0-2 [18] [19] [20] , including our current cohort, which showed that 70.8% of patients are categorized as CLIP 0-2 ( table 2 ) . Therefore, there is an immediate need to improve the stratification ability and accuracy of the CLIP score. Our recent studies showed that integrating the plasma level of vascular endothelial growth factor and insulin-like growth factor-1 into CLIP score parameters, V-CLIP [13] and I-CLIP [14] , significantly improved the survival prediction and risk stratification of patients with HCC. Future validation studies in patients with different demographics and HCC risk factors are warranted.
Taken together, our study results indicate major challenges in accurate prediction of survival and optimal risk stratification of patients with nonsurgical HCC based on the currently available HCC staging systems which were originally developed from different patient populations, with different prevalences of hepatitis and cirrhosis, in addition to different demographics and geographical location. These observations of the differential effects of hepatitis and cirrhosis status, demographics and geographical location on prognostic stratification of HCC is consistent with similar observations in patients with HCC treated with trans-arterial chemoembolization from the two randomized studies conducted in Europe [21] and Asia [22] , with an 87% HCV infection rate [21] and 80% HBV infec-
